• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酶切破坏 CD 环通过一种常见的转甲状腺素蛋白错误折叠途径促进毒性转甲状腺素蛋白寡聚物的形成。

Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway.

机构信息

Department of Chemistry, East Carolina University, Greenville, North Carolina 27858, United States.

Department of Chemistry and Francis Bitter Magnet Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.

出版信息

Biochemistry. 2020 Jun 30;59(25):2319-2327. doi: 10.1021/acs.biochem.0c00079. Epub 2020 Jun 14.

DOI:10.1021/acs.biochem.0c00079
PMID:32500705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7339286/
Abstract

Amyloid formation of full-length TTR involves dissociation of the native tetramers into misfolded monomers that self-assemble into amyloid. In addition to the full-length TTR, C-terminal fragments including residues 49-127 were also observed , implying the presence of additional misfolding pathways. It was previously proposed that a proteolytic cleavage might lead to the formation of the C-terminal fragment TTR amyloid. Here, we report mechanistic studies of misfolding and aggregation of a TTR variant (G53A) in the absence and presence of a serine protease. A proteolytic cleavage of G53A in the CD loop (K48 and T49) with agitation promoted TTR misfolding and aggregation, suggesting that the proteolytic cleavage may lead to the aggregation of the C-terminal fragment (residues 49-127). To gain more detailed insights into TTR misfolding promoted by proteolytic cleavage, we investigated structural changes in G53A TTR in the presence and absence of trypsin. Our combined biophysical analyses revealed that the proteolytic cleavage accelerated the formation of spherical small oligomers, which exhibited cytotoxic activities. However, the truncated TTR appeared to maintain native-like structures, rather than the C-terminal fragment (residues 49-127) being released and unfolded from the native state. In addition, our solid-state nuclear magnetic resonance and Fourier transform infrared structural studies showed that the two aggregates derived from the full-length and cleaved TTR exhibited nearly identical molecular structural features, suggesting that the proteolytic cleavage in the CD loop destabilizes the native tetrameric structure and accelerates oligomer formation through a common TTR misfolding and aggregation mechanism rather than through a distinct molecular mechanism.

摘要

全长 TTR 的淀粉样蛋白形成涉及到天然四聚体的解离,形成错误折叠的单体,这些单体自组装成淀粉样蛋白。除了全长 TTR 外,还观察到包括残基 49-127 的 C 端片段,这表明存在额外的错误折叠途径。先前有人提出,蛋白水解切割可能导致 C 端片段 TTR 淀粉样蛋白的形成。在这里,我们报告了在缺乏和存在丝氨酸蛋白酶的情况下,TTR 变体(G53A)错误折叠和聚集的机制研究。在搅拌下,G53A 在 CD 环(K48 和 T49)上的蛋白水解切割促进了 TTR 的错误折叠和聚集,表明蛋白水解切割可能导致 C 端片段(残基 49-127)的聚集。为了更详细地了解蛋白水解切割促进的 TTR 错误折叠,我们研究了在有和没有胰蛋白酶存在的情况下 G53A TTR 的结构变化。我们的综合生物物理分析表明,蛋白水解切割加速了球形小寡聚物的形成,这些寡聚物表现出细胞毒性活性。然而,截断的 TTR 似乎保持了类似天然的结构,而不是 C 端片段(残基 49-127)从天然状态中释放和展开。此外,我们的固态核磁共振和傅里叶变换红外结构研究表明,来自全长和切割 TTR 的两种聚集体表现出几乎相同的分子结构特征,这表明 CD 环中的蛋白水解切割破坏了天然四聚体结构,并通过共同的 TTR 错误折叠和聚集机制加速寡聚体形成,而不是通过独特的分子机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/dc6aaa52a10a/nihms-1605923-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/6bb690b26752/nihms-1605923-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/0e522742eeac/nihms-1605923-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/f4b43801eee0/nihms-1605923-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/0eb88ecd9d6b/nihms-1605923-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/a5b8495e8b06/nihms-1605923-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/dc6aaa52a10a/nihms-1605923-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/6bb690b26752/nihms-1605923-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/0e522742eeac/nihms-1605923-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/f4b43801eee0/nihms-1605923-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/0eb88ecd9d6b/nihms-1605923-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/a5b8495e8b06/nihms-1605923-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b4/7339286/dc6aaa52a10a/nihms-1605923-f0007.jpg

相似文献

1
Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway.酶切破坏 CD 环通过一种常见的转甲状腺素蛋白错误折叠途径促进毒性转甲状腺素蛋白寡聚物的形成。
Biochemistry. 2020 Jun 30;59(25):2319-2327. doi: 10.1021/acs.biochem.0c00079. Epub 2020 Jun 14.
2
Identification of the interfacial regions in misfolded transthyretin oligomers.鉴定错误折叠转甲状腺素蛋白寡聚物的界面区域。
Biochim Biophys Acta Proteins Proteom. 2024 Sep 1;1872(5):141027. doi: 10.1016/j.bbapap.2024.141027. Epub 2024 May 23.
3
Toxic Misfolded Transthyretin Oligomers with Different Molecular Conformations Formed through Distinct Oligomerization Pathways.毒性错误折叠转甲状腺素蛋白寡聚物具有不同的分子构象,通过不同的寡聚化途径形成。
Biochemistry. 2022 Nov 1;61(21):2358-2365. doi: 10.1021/acs.biochem.2c00390. Epub 2022 Oct 11.
4
Transthyretin Aggregation Pathway toward the Formation of Distinct Cytotoxic Oligomers.转甲状腺素蛋白聚集途径导致不同细胞毒性寡聚物的形成。
Sci Rep. 2019 Jan 10;9(1):33. doi: 10.1038/s41598-018-37230-1.
5
Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.丝氨酸 52 脯氨酸变异转甲状腺素蛋白的蛋白水解裂解触发其淀粉样纤维形成。
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1539-44. doi: 10.1073/pnas.1317488111. Epub 2014 Jan 13.
6
Two distinct aggregation pathways in transthyretin misfolding and amyloid formation.两种不同的转甲状腺素蛋白错误折叠和淀粉样纤维形成的聚集途径。
Biochim Biophys Acta Proteins Proteom. 2019 Mar;1867(3):344-349. doi: 10.1016/j.bbapap.2018.10.013. Epub 2018 Oct 24.
7
Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.硫酸化糖胺聚糖通过四级结构转换加速转甲状腺素蛋白淀粉样变性。
Biochemistry. 2011 Feb 15;50(6):1001-15. doi: 10.1021/bi101822y. Epub 2011 Jan 24.
8
Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.人甲状腺素运载蛋白表面环中的异常重复突变导致侵袭性耐药淀粉样变性疾病。
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6428-E6436. doi: 10.1073/pnas.1802977115. Epub 2018 Jun 25.
9
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.冠醚类作为转甲状腺素蛋白淀粉样变性抑制剂。
J Med Chem. 2019 Feb 28;62(4):2076-2082. doi: 10.1021/acs.jmedchem.8b01700. Epub 2019 Feb 8.
10
Structural Characterization of Cardiac Ex Vivo Transthyretin Amyloid: Insight into the Transthyretin Misfolding Pathway In Vivo.心脏离体转甲状腺素蛋白淀粉样变的结构特征:深入了解转甲状腺素蛋白在体内的错误折叠途径
Biochemistry. 2020 May 19;59(19):1800-1803. doi: 10.1021/acs.biochem.0c00091. Epub 2020 Apr 30.

引用本文的文献

1
Aggregation of Transthyretin by Fluid Agitation.通过液体搅拌使转甲状腺素蛋白聚集。
bioRxiv. 2024 Nov 11:2024.11.08.622726. doi: 10.1101/2024.11.08.622726.
2
Structure-Based Probe Reveals the Presence of Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis Patients.基于结构的探针揭示了转甲状腺素蛋白淀粉样变性患者血浆中存在大量转甲状腺素蛋白聚集体。
JACC Basic Transl Sci. 2024 Jul 17;9(9):1088-1100. doi: 10.1016/j.jacbts.2024.05.013. eCollection 2024 Sep.
3
Identification of the interfacial regions in misfolded transthyretin oligomers.

本文引用的文献

1
Structural Characterization of Cardiac Ex Vivo Transthyretin Amyloid: Insight into the Transthyretin Misfolding Pathway In Vivo.心脏离体转甲状腺素蛋白淀粉样变的结构特征:深入了解转甲状腺素蛋白在体内的错误折叠途径
Biochemistry. 2020 May 19;59(19):1800-1803. doi: 10.1021/acs.biochem.0c00091. Epub 2020 Apr 30.
2
Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.遗传性转甲状腺素淀粉样变性患者源性转甲状腺素蛋白衍生淀粉样纤维的冷冻电镜结构。
Nat Commun. 2019 Nov 1;10(1):5008. doi: 10.1038/s41467-019-13038-z.
3
Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.
鉴定错误折叠转甲状腺素蛋白寡聚物的界面区域。
Biochim Biophys Acta Proteins Proteom. 2024 Sep 1;1872(5):141027. doi: 10.1016/j.bbapap.2024.141027. Epub 2024 May 23.
4
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy.转甲状腺素蛋白稳定剂和种子抑制剂作为转甲状腺素蛋白淀粉样心肌病的治疗方法
Pharmaceutics. 2023 Apr 3;15(4):1129. doi: 10.3390/pharmaceutics15041129.
5
A molecular basis for tetramer destabilization and aggregation of transthyretin Ala97Ser.转甲状腺素蛋白 Ala97Ser 四聚体不稳定和聚集的分子基础。
Protein Sci. 2023 Apr;32(4):e4610. doi: 10.1002/pro.4610.
6
Liver-directed drugs for transthyretin-mediated amyloidosis.针对转甲状腺素蛋白介导淀粉样变性的肝靶向药物。
J Peripher Nerv Syst. 2022 Dec;27(4):228-237. doi: 10.1111/jns.12519. Epub 2022 Nov 16.
7
Toxic Misfolded Transthyretin Oligomers with Different Molecular Conformations Formed through Distinct Oligomerization Pathways.毒性错误折叠转甲状腺素蛋白寡聚物具有不同的分子构象,通过不同的寡聚化途径形成。
Biochemistry. 2022 Nov 1;61(21):2358-2365. doi: 10.1021/acs.biochem.2c00390. Epub 2022 Oct 11.
8
Structural basis for transthyretin amyloid formation in vitreous body of the eye.眼玻璃体中原甲状腺素蛋白淀粉样形成的结构基础。
Nat Commun. 2021 Dec 8;12(1):7141. doi: 10.1038/s41467-021-27481-4.
9
Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future.遗传性转甲状腺素蛋白淀粉样变性的现有和新兴疗法:迈向更光明的未来。
Neurotherapeutics. 2021 Oct;18(4):2286-2302. doi: 10.1007/s13311-021-01154-y. Epub 2021 Nov 30.
10
Aggregation-Prone Structural Ensembles of Transthyretin Collected With Regression Analysis for NMR Chemical Shift.通过回归分析收集用于核磁共振化学位移的甲状腺素运载蛋白的易聚集结构集合。
Front Mol Biosci. 2021 Oct 20;8:766830. doi: 10.3389/fmolb.2021.766830. eCollection 2021.
遗传性转甲状腺素蛋白淀粉样变性病:致命疾病的医学进步典范。
Nat Rev Neurol. 2019 Jul;15(7):387-404. doi: 10.1038/s41582-019-0210-4. Epub 2019 Jun 17.
4
Transthyretin Aggregation Pathway toward the Formation of Distinct Cytotoxic Oligomers.转甲状腺素蛋白聚集途径导致不同细胞毒性寡聚物的形成。
Sci Rep. 2019 Jan 10;9(1):33. doi: 10.1038/s41598-018-37230-1.
5
Plasminogen activation triggers transthyretin amyloidogenesis .纤溶酶原激活触发转甲状腺素蛋白淀粉样变性。
J Biol Chem. 2018 Sep 14;293(37):14192-14199. doi: 10.1074/jbc.RA118.003990. Epub 2018 Jul 17.
6
Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.人甲状腺素运载蛋白表面环中的异常重复突变导致侵袭性耐药淀粉样变性疾病。
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6428-E6436. doi: 10.1073/pnas.1802977115. Epub 2018 Jun 25.
7
Kinetic analysis of the multistep aggregation pathway of human transthyretin.人甲状腺素运载蛋白多步骤聚集途径的动力学分析。
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6201-E6208. doi: 10.1073/pnas.1807024115. Epub 2018 Jun 18.
8
hIAPP forms toxic oligomers in plasma.hIAPP 在血浆中形成毒性寡聚物。
Chem Commun (Camb). 2018 May 24;54(43):5426-5429. doi: 10.1039/c8cc03097a.
9
Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy.转甲状腺素蛋白淀粉样变性:一种未被充分认识的神经病变和心肌病。
Clin Sci (Lond). 2017 Mar 1;131(5):395-409. doi: 10.1042/CS20160413.
10
Amyloid Fibres: Inert End-Stage Aggregates or Key Players in Disease?淀粉样纤维:无活性的终末聚集物还是疾病的关键参与者?
Trends Biochem Sci. 2015 Dec;40(12):719-727. doi: 10.1016/j.tibs.2015.10.002. Epub 2015 Nov 2.